{"id":"saredutant-sr48968","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"5-20%","effect":"Diarrhea"},{"rate":"5-20%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the NK1 receptor, saredutant is intended to prevent the action of substance P, a neurotransmitter involved in the transmission of pain signals. This mechanism is thought to be beneficial in the treatment of chemotherapy-induced nausea and vomiting.","oneSentence":"Saredutant is an antagonist of the neurokinin-1 (NK1) receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:34.158Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced nausea and vomiting"}]},"trialDetails":[{"nctId":"NCT00256113","phase":"PHASE3","title":"An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-12","conditions":"Depressive Disorder","enrollment":467},{"nctId":"NCT00629551","phase":"PHASE3","title":"An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-02","conditions":"Depressive Disorder, Major","enrollment":825},{"nctId":"NCT00415142","phase":"PHASE3","title":"An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-12","conditions":"Depressive Disorder","enrollment":393},{"nctId":"NCT00417118","phase":"PHASE3","title":"An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-12","conditions":"Generalized Anxiety","enrollment":365},{"nctId":"NCT00531622","phase":"PHASE3","title":"An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-09","conditions":"Major Depressive Disorder","enrollment":643},{"nctId":"NCT00390533","phase":"PHASE3","title":"An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-09","conditions":"Generalized Anxiety","enrollment":428},{"nctId":"NCT00336713","phase":"PHASE3","title":"A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-05","conditions":"Depressive Disorder","enrollment":430},{"nctId":"NCT00429260","phase":"PHASE3","title":"A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-01","conditions":"Depressive Disorder","enrollment":125},{"nctId":"NCT00250601","phase":"PHASE3","title":"An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-04","conditions":"Depressive Disorder","enrollment":460},{"nctId":"NCT00250653","phase":"PHASE3","title":"A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-05","conditions":"Depressive Disorder","enrollment":365},{"nctId":"NCT00390650","phase":"PHASE3","title":"A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-10","conditions":"Anxiety","enrollment":366},{"nctId":"NCT00250614","phase":"PHASE3","title":"An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-04","conditions":"Depressive Disorder","enrollment":452},{"nctId":"NCT00250627","phase":"PHASE3","title":"An Eight-Week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-12","conditions":"Depressive Disorder","enrollment":465}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":149,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"saredutant (SR48968)","genericName":"saredutant (SR48968)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Saredutant, also known as SR48968, is a small molecule that acts as a neurokinin 2 receptor antagonist. It has been studied in clinical trials for the treatment of depressive disorder, anxiety, and generalized anxiety.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}